Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201

Inclusion Criteria: 1. Written informed consent obtained prior to any study-related procedure being performed 2. Previous, uninterrupted enrollment and treatment in trial number CHL-AA-201. Exclusion Criteria: 1. Progressive disease as ascertained by the investigator using standard-of-care evaluations. 2. CHL-AA-201 D84 blood counts of the following: 1. Absolute neutrophil count \> 1500/µL 2. Platelets \> 100,000/µL 3. Hemoglobin \> 9 g/dL 3. CHL-AA-201 D84 chemistry values of the following: 1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x Upper Limit of Normal (ULN) 2. Total bilirubin \< 1.5 x ULN 3. Creatinine\< 1.5 x ULN 4. Albumin \> 3.0 g/dL 5. Potassium \> 3.5 mmol/L